Compare Divis Laboratories with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SUN PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SUN PHARMA DIVIS LABORATORIES/
SUN PHARMA
 
P/E (TTM) x 50.3 30.9 162.8% View Chart
P/BV x 11.6 4.2 277.6% View Chart
Dividend Yield % 0.5 0.9 53.1%  

Financials

 DIVIS LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-21
SUN PHARMA
Mar-21
DIVIS LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,913654 598.6%   
Low Rs1,824339 538.7%   
Sales per share (Unadj.) Rs262.5139.6 188.0%  
Earnings per share (Unadj.) Rs74.79.5 785.0%  
Cash flow per share (Unadj.) Rs84.418.2 463.8%  
Dividends per share (Unadj.) Rs20.007.50 266.7%  
Avg Dividend yield %0.71.5 46.1%  
Book value per share (Unadj.) Rs350.1193.6 180.8%  
Shares outstanding (eoy) m265.472,399.34 11.1%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x10.93.6 307.5%   
Avg P/E ratio x38.452.1 73.7%  
P/CF ratio (eoy) x34.027.3 124.7%  
Price / Book Value ratio x8.22.6 319.8%  
Dividend payout %26.878.8 34.0%   
Avg Mkt Cap Rs m761,5171,190,430 64.0%   
No. of employees `000NANA-   
Total wages/salary Rs m8,25868,622 12.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m69,694334,981 20.8%  
Other income Rs m6278,592 7.3%   
Total revenues Rs m70,321343,573 20.5%   
Gross profit Rs m28,61141,616 68.7%  
Depreciation Rs m2,55620,800 12.3%   
Interest Rs m211,414 1.5%   
Profit before tax Rs m26,66027,994 95.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,8185,147 132.5%   
Profit after tax Rs m19,84322,847 86.9%  
Gross profit margin %41.112.4 330.4%  
Effective tax rate %25.618.4 139.1%   
Net profit margin %28.56.8 417.5%  
BALANCE SHEET DATA
Current assets Rs m67,906304,421 22.3%   
Current liabilities Rs m17,284161,456 10.7%   
Net working cap to sales %72.642.7 170.2%  
Current ratio x3.91.9 208.4%  
Inventory Days Days10149 6.4%  
Debtors Days Days87899 889.3%  
Net fixed assets Rs m45,963336,682 13.7%   
Share capital Rs m5312,399 22.1%   
"Free" reserves Rs m92,415462,229 20.0%   
Net worth Rs m92,946464,628 20.0%   
Long term debt Rs m08,981 0.0%   
Total assets Rs m113,869641,103 17.8%  
Interest coverage x1,270.520.8 6,110.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.5 117.1%   
Return on assets %17.43.8 461.0%  
Return on equity %21.34.9 434.2%  
Return on capital %28.76.2 462.3%  
Exports to sales %00-   
Imports to sales %18.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m13,127NA-   
Fx inflow Rs m58,87784,493 69.7%   
Fx outflow Rs m13,34130,334 44.0%   
Net fx Rs m45,53654,159 84.1%   
CASH FLOW
From Operations Rs m19,46961,704 31.6%  
From Investments Rs m7515,362 14.0%  
From Financial Activity Rs m-349-59,805 0.6%  
Net Cashflow Rs m19,8725,964 333.2%  

Share Holding

Indian Promoters % 52.0 54.5 95.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.0 34.0 108.9%  
FIIs % 19.3 13.0 148.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.1 45.5 105.6%  
Shareholders   274,505 680,800 40.3%  
Pledged promoter(s) holding % 0.0 4.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    CADILA HEALTHCARE    



Today's Market

Sensex, Nifty Recover from Day's Low to End Higher; Maruti Suzuki Hits New High Post Q3 Results(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

SUN PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 22, 2021 | Updated on Oct 22, 2021

Here's an analysis of the annual report of SUN PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

DIVIS LABORATORIES 2020-21 Annual Report Analysis (Annual Result Update)

Oct 20, 2021 | Updated on Oct 20, 2021

Here's an analysis of the annual report of DIVIS LABORATORIES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates (Views On News)

Jul 30, 2021

Here's a rundown on Sun Pharma's June quarter results.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

5 Hidden Tata Group Companies to Add to Your Watchlist(Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 25, 2022 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS